Komori
Disclosure4539NIPPON CHEMIPHAR CO.,LTD.Pharmaceuticals

Notice Concerning the Recognition of Adjustments to Corporate Income Taxes (Tax Benefit)

Following a review of the recoverability of deferred tax assets based on estimates of future taxable income, the company recorded an income taxes adjustment benefit of ¥137 million for the second quarter of the fiscal year ending March 2027 and ¥218 million on a cumulative interim-period basis.

Worth reading
69In focus
Scored from 4 of 6 sections
Direction
Improvement
Direction inferred from the company’s description.
Scale
218
¥ million
Wording
Conditional
How definitive the wording is.

Decision and Details

Recognition of a gain on income taxes—deferred

Period CoveredThe interim consolidated accounting period of the fiscal year ending March 2027 (1 April 2026 to 30 September 2026)
ImplementationRecorded (actual) in the consolidated accounting period for the second quarter of the fiscal year ending March 2027 (1 April 2026 to 30 September 2026)
AmountSecond quarter of the fiscal year ending March 2027: income taxes adjustment benefit of ¥137 million; interim period of the fiscal year ending March 2027: income taxes adjustment benefit of ¥218 million
Reason

Because, based on estimates of future taxable income as of the current date, the company reviewed the recoverability of deferred tax assets and recorded the portion expected to be recovered

Impact on Business Performance

Recorded in the consolidated financial results for the interim period of the fiscal year ending March 2027

Decision and Details
ItemDetails
Matter CoveredRecognition of a gain on income taxes—deferred
Implementation DateRecorded (actual) in the consolidated accounting period for the second quarter of the fiscal year ending March 2027 (1 April 2026 to 30 September 2026)
Period CoveredThe interim consolidated accounting period of the fiscal year ending March 2027 (1 April 2026 to 30 September 2026)
AmountSecond quarter of the fiscal year ending March 2027: income taxes adjustment benefit of ¥137 million; interim period of the fiscal year ending March 2027: income taxes adjustment benefit of ¥218 million
Impact on Business PerformanceRecorded in the consolidated financial results for the interim period of the fiscal year ending March 2027
ReasonBecause, based on estimates of future taxable income as of the current date, the company reviewed the recoverability of deferred tax assets and recorded the portion expected to be recovered
Items this document does not state (6)
Decision-Making BodyDecision DateQuantity / scaleGoverning RuleRelated previous disclosuresFuture plans

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Based on an estimate of future taxable income as of the present time and an assessment of the recoverability of deferred tax assets, the Company recognized the portion expected to be recovered.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Concerning the Recognition of Adjustments to Corporate Income Taxes (Tax Benefit) | NIPPON CHEMIPHAR CO.,LTD. (4539) timely disclosure | Komori